COMMUNIQUÉ DE PRESSE publié le 30/11/2023 à 14:30, il y a 2 années 5 mois Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy Crofelemer Jaguar Health Oncology Investor Conference Phase 3 Clinical Trial Cancer Therapy
COMMUNIQUÉ DE PRESSE publié le 21/11/2023 à 14:30, il y a 2 années 6 mois Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
COMMUNIQUÉ DE PRESSE publié le 14/11/2023 à 14:00, il y a 2 années 6 mois Jaguar Health Reports Third Quarter 2023 Financial Results
COMMUNIQUÉ DE PRESSE publié le 10/11/2023 à 22:15, il y a 2 années 6 mois Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
COMMUNIQUÉ DE PRESSE publié le 09/11/2023 à 14:30, il y a 2 années 6 mois Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
COMMUNIQUÉ DE PRESSE publié le 08/11/2023 à 16:25, il y a 2 années 6 mois Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
COMMUNIQUÉ DE PRESSE publié le 08/11/2023 à 14:30, il y a 2 années 6 mois Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
COMMUNIQUÉ DE PRESSE publié le 07/11/2023 à 14:30, il y a 2 années 6 mois REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
COMMUNIQUÉ DE PRESSE publié le 02/11/2023 à 13:30, il y a 2 années 6 mois Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
COMMUNIQUÉ DE PRESSE publié le 01/11/2023 à 13:30, il y a 2 années 6 mois Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Publié le 22/05/2026 à 12:52, il y a 5 heures 15 minutes Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Publié le 22/05/2026 à 12:52, il y a 5 heures 15 minutes Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Publié le 22/05/2026 à 08:30, il y a 9 heures 38 minutes Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Publié le 22/05/2026 à 08:30, il y a 9 heures 38 minutes Eiffage réalise quatre centrales photovoltaïques dans le cadre du programme NOOR Atlas au Maroc
Publié le 22/05/2026 à 14:04, il y a 4 heures 4 minutes Wi2Wi Corporation Announces First Quarter 2026 Financial Results (Unaudited)
Publié le 22/05/2026 à 14:00, il y a 4 heures 8 minutes Imagine Health Achieves Teaching Facility Status Through University of Calgary Faculty Partnership
Publié le 22/05/2026 à 14:00, il y a 4 heures 8 minutes CCL Industries Inc. Announces Renewal of Normal Course Issuer Bid and Approval of Automatic Securities Purchase Plan
Publié le 22/05/2026 à 14:00, il y a 4 heures 8 minutes Dateline Appoints Alvarez & Marsal to Manage Colosseum Development
Publié le 22/05/2026 à 14:00, il y a 4 heures 8 minutes EQ Inc. Reports First Quarter 2026 Financial Results and Annual General Meeting Results
Publié le 22/05/2026 à 17:18, il y a 50 minutes Chief Human Resources Officer Dr. Astrid Fontaine’s contract extended
Publié le 22/05/2026 à 17:05, il y a 1 heure 3 minutes hep global GmbH wins financial investor FH Capital to strengthen US business
Publié le 22/05/2026 à 16:44, il y a 1 heure 23 minutes 2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items
Publié le 22/05/2026 à 16:38, il y a 1 heure 29 minutes SoftwareOne shareholders approve all proposals of the Board of Directors at the 2026 Annual General Meeting
Publié le 22/05/2026 à 15:30, il y a 2 heures 37 minutes Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
